The Pfizer/BioNTech coronavirus disease 2019 vaccine can be stored at higher temperatures; the Biden administration pledges $4 billion over 2 years to Gavi, the Vaccine Alliance; Medicare payments will soon decrease for hundreds of hospitals.
New coronavirus disease 2019 (COVID-19) vaccine storage and effectiveness data from Sheba Medical Center in Israel show that the first dose of Pfizer/BioNTech’s vaccine is 85% effective 15 to 28 days after it is given, reports The Wall Street Journal. Transportation and storage at temperatures of –25°C (–13°F) to –15°C (5°F), vs the current –80°C (–112°F) to –60°C (–76°F), are also possible according to the real-world data. These findings could enable more to get an initial dose of the vaccine, as the results “provide strong arguments in favor of delaying the second dose of the 2-shot vaccine,” the authors note. Close to 9000 individuals were covered in this study, in which the first dose also resulted in 75% reductions in symptomatic and asymptomatic infections.
Up to $4 billion in funding for Gavi, the Vaccine Alliance, could be possible through a new push from President Joe Biden and his administration, according to The Washington Post. This money would provide some much-needed aid to COVID-19 Vaccines Global Access, or COVAX, which has yet to begin vaccine delivery. An initial $2 billion would be released first, followed by another $2 billion over 2 years, pending pledge follow-through from other potential donors. The World Health Organization and the Coalition for Epidemic Preparedness Innovations are Gavi’s partners in this effort to ensure equitable vaccine distribution to low- and middle-income countries.
High patient infection rates and avoidable medical complications from mid-2017 through 2019 have spurred the government’s move to reduce Medicare payments to 774 hospitals, says Kaiser Health News. The 1% reduction, as part of a program instituted by the Affordable Care Act, will be implemented over 12 months and is not related to the ongoing pandemic. Controversy has plagued the Hospital-Acquired Condition Reduction Program since its inception, with hospitals claiming penalties are arbitrary and the American Hospital Association saying the hard-and-fast rule of punishing 25% of general-care hospitals each year is a flawed measure.
Personalized Care Key as Tirzepatide Use Expands Rapidly
April 15th 2025Using commercial insurance claims data and the US launch of tirzepatide as their dividing point, John Ostrominski, MD, Harvard Medical School, and his team studied trends in the use of both glucose-lowering and weight-lowering medications, comparing outcomes between adults with and without type 2 diabetes.
Listen
SGLT2 Inhibitors Show Renal Benefits in HF and CKD as Prescribers Target Uptake Gaps
April 15th 2025Abstracts featured at the National Kidney Foundation Spring Clinical Meeting highlighted the renoprotective benefits of SGLT2 inhibitors in heart failure and diabetic kidney disease while emphasizing the need for strategies to increase their uptake in primary care.
Read More
Health Equity & Access Weekly Roundup: April 14, 2025
April 14th 2025From the potential impact of tariffs to the World Health Organization's year-long campaign launch focused on improving maternal and newborn health and addressing preventable deaths, here's the latest from the Center on Health Equity & Access.
Read More